The observation of delayed viral rebound and/or viremia control at any point during analytical treatment interruption was low, with only 3 out ... of its Phase 1/2 STRIVE trial of IMC-M113V ...

Dogwood Therapeutics, Inc. has announced the dosing of the first patient in its Phase 2b clinical trial, HALT-CINP, which studies Halneuron® as a treatment for chemotherapy-induced neuropathic pain.

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) ("Dogwood” or the "Company”), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid, treatments for chronic and acute ...

Proceeds from today’s financing, when added to existing cash, fund operations through Q1 2026The Company is planning to announce interim data ...

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025IMC-M113V was well ...

Q4 2024 Earnings Call Transcript March 20, 2025 Operator: Hello, everyone, and thank you for joining 111’s Conference Call ...

The Company is planning to announce interim data from its ongoing Halneuron ® Phase 2b chemotherapy induced neuropathic pain (“CINP”) trial in Q4 2025 ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) — ...

Chairman of the Board, Chief Executive Officer, Co-Founder; 111 Inc. Luke Chen; Chief Financial Officer; 111 Inc. Gang Yu; Executive Chairman, Co-Fou ...

If you can find the well-known casino you can get, revamp, and set back on typically the map, this can be the better choice.

Thank you for standing by and welcome to the T1 Energy fourth-quarter 2024 earnings conference call. (Operator Instructions) Thank you. I'd now like to turn the call over to Jeffrey Spittel, EVP ...

Q4 2024 Earnings Conference Call March 17, 2025 8:00 AM ETCompany ParticipantsJeffrey Spittel - VP, IRDaniel Barcelo - ...